NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Rubedo Life Sciences

Rubedo Life Sciences

Private
Sunnyvale, CaliforniaHealthcare & Life Scienceshttps://www.rubedolife.com/

Last Round

Series A

Apr 22, 2024

Total Funding Raised

$53.45M

Company Overview

Rubedo Life Sciences is a biopharmaceutical company that develops therapies for chronic age-related diseases by targeting senescent cells.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Infrastructure

Keywords

senolytic therapysenescent cellsdrug discovery platformAI drug discoverylongevity biotechGPX4 modulatorage-related diseaseclinical-stage biotechALEMBICmulti-omicssmall molecule therapeuticanti-aging medicinecomputational biologyscRNA-seqbiotech startup

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Rubedo Life Sciences Comparables

Compare Rubedo Life Sciences with similar companies based on industry and business-model similarity.

Rubedo Life Sciences comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Deciduous Therapeutics
89%
Cleara Biotech
84%
StarkAge Therapeutics
82%

Rubedo Life Sciences Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AApr 22, 2024
GrantFeb 6, 2023
SeedDec 3, 2020

Key People

Founding team and executive leadership

Frederick Beddingfield

CEO And Director

Executive Team

Alex Laslavic

Chief Technology Officer

Executive Team

Marco Dotto

Chief Operating Officer, Director Of The Board, Angel Investor

Executive Team

Rubedo Life Sciences Investors

Notable investors and investment history

Rubedo Life Sciences investors
InvestorRounds
Refactor CapitalSeed, Series A
Khosla VenturesSeed, Series A
age1Seed
Hevolution FoundationSeries A
LongeVCSeries A
Longevity FundSeed
California Institute for Regenerative MedicineGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 22, 2025

    First patient dosed in Phase 1 trial for RLS-1496.

  • Jan 1, 2025

    Presented at the 12th Annual Dermatology Summit.

Rubedo Life Sciences Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Rubedo Life Sciences Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Rubedo Life Sciences's valuation, stock price, and market status.

Firmographic Details

HeadquartersSunnyvale, California
Employee Range34
Year Founded2018
Last FundingApr 22, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.